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Chemotaxis of dendritic cells (DCs) and monocytes is a key step in the initiation of an 
adequate immune response. Formyl peptide receptor (FPR) and FPR-like receptor (FPRL)1, 
two G protein–coupled receptors belonging to the FPR family, play an essential role in host 
defense mechanisms against bacterial infection and in the regulation of inflammatory 
reactions. FPRL2, the third member of this structural family of chemoattractant receptors, 
is characterized by its specific expression on monocytes and DCs. Here, we present the 
isolation from a spleen extract and the functional characterization of F2L, a novel 
chemoattractant peptide acting specifically through FPRL2. F2L is an acetylated amino-
terminal peptide derived from the cleavage of the human heme-binding protein, an 
intracellular tetrapyrolle-binding protein. The peptide binds and activates FPRL2 in the low 
nanomolar range, which triggers intracellular calcium release, inhibition of cAMP 
accumulation, and phosphorylation of extracellular signal–regulated kinase 1/2 mitogen-
activated protein kinases through the G
 
i 
 
class of heterotrimeric G proteins. When tested on 
monocytes and monocyte-derived DCs, F2L promotes calcium mobilization and chemotaxis. 
Therefore, F2L appears as a new natural chemoattractant peptide for DCs and monocytes, 
and the first potent and specific agonist of FPRL2.
 
DCs and monocytes are critical players in host
immune mechanisms. They are able to sense
danger signals of diverse origins (various path-
ogen classes and tissular disturbances such as
necrosis and tumor development; reference 1).
They are attracted during early phases of
inflammatory reactions by a diverse set of
chemoattractant molecules, including chemo-
kines, the complement factor C5a, the bacte-
rial peptide FMLP, the lipid metabolite PAF,
and the recently identified chemerin (1, 2).
Locally, these cells participate to innate immu-
nity through the phagocytosis of microbes or
diseased cells and the secretion of a range of
bioactive mediators, including cytokines and
chemokines. Immature DCs take up and pro-
cess available antigens and then, under ap-
propriate stimuli, undergo maturation, switch
their expression of chemokine receptors from
inflammatory to lymphoid homing receptors,
and migrate to the draining lymph nodes
where they interact with T cells to initiate an
appropriate immune response. These various
populations of antigen-presenting cells are ex-
tremely heterogeneous in terms of morphology
and function. These functional differences are
partly related to the set of chemoattractant
seven-transmembrane, G protein–coupled re-
ceptors (GPCRs) they express.
In the 1970’s, synthetic FMLP was one of
the first identified potent leukocyte chemoattrac-
tants. Natural FMLP was later purified from
Gram-negative bacteria (3, 4). Its human re-
ceptor, formyl peptide receptor (FPR), was
cloned in 1990 from a differentiated HL-60
myeloid leukemia cell cDNA library (5).
Two human genes encoding the structurally
related receptors FPR-like receptor (FPRL)1
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and FPRL2 were subsequently cloned by low stringency
hybridization using FPR cDNA as a probe, and shown to
cluster with FPR on human chromosome 19q13.3 (6, 7). In
contrast, the murine FPR gene family comprises at least
eight distinct genes (Fpr1 and Fpr-rs 1–7), of which six are
clustered on chromosome 17, in a region of conserved syn-
teny with human chromosome 19 (8, 9). Fpr1 is considered
the murine orthologue of FPR, whereas Fpr-rs1 and Fpr-rs2
share structural and functional similarity with FPRL1. No
obvious orthologue of FPRL2 can be determined from a
structural viewpoint. Therefore, it appears that the FPR
gene cluster has undergone recent and independent gene du-
plications in various mammalian species, which may also im-
ply functional divergence of the resulting receptor subtypes.
FPR is a high affinity receptor for formyl peptides. Syn-
thetic W hexapeptides were described as efficient surrogate ag-
onists of FPR, whereas the receptor was also reported to re-
spond to HIV-derived peptides, amino-terminal peptides of
annexin I, and cathepsin G, although with relatively low po-
tencies (10–12). FPRL1 shares 69% amino acid identity with
FPR and displays low affinity for FMLP. However, FPRL1
appears as a remarkably promiscuous receptor, as it is activated
by numerous and chemically unrelated ligands. These include
the following: the synthetic peptides MMK1 and W hexapep-
tides; pathogen-derived peptides such as the Hp 2–20 peptide
from 
 
Helicobacter pylori
 
 and peptides derived from HIV gp41
and gp120; the lipid lipoxin A4; as well as a variety of host
proteins and peptides such as cathelicidin LL37, annexin I and
the Ac1-25 and Ac1-11 peptides derived from this protein, the
88–274 fragment of the urokinase receptor, the serum amyloid
A protein, the amyloid 
 
  
 
peptide A
 
 
 
42, the prion protein
fragment P106-126, a fragment from the mitochondrial
NADH dehydrogenase subunit I, a truncated form of the che-
mokine CK
 
 
 
8-1, and the neuroprotective peptide humanin
(3, 4, 13, 14). However, the affinity of FPRL1 for these vari-
ous ligands is often low, and the functional relevance of these
interactions is therefore questionable. FPRL2 shares 56 and
83% amino acid identity with FPR and FPRL1, respectively.
FPRL2 does not respond to formyl peptides, but it was de-
scribed as a low affinity receptor for several FPRL1 agonists,
namely the annexin I amino-terminal peptide Ac1-25 (15) and
the 
 
H. pylori
 
–derived peptide Hp 2–20 (16, 17). The synthetic
hexapeptides WKYMVM and WKYMVm were also de-
scribed to act partly through FPRL2 on leukocyte populations
expressing various combinations of the FPRs and on recombi-
nant cells expressing FPRL2 (18, 19). Therefore, no high af-
finity endogenous ligand has so far been identified for FPRL2,
which can be considered essentially an orphan receptor.
Interestingly, the three FPRs display a quite different ex-
pression profile on phagocytic leukocytes. Neutrophils express
functional FPR and FPRL1. Monocytes express the three re-
ceptors at their surface, whereas monocyte-derived DCs ex-
press FPR and FPRL2 when immature and only retain FPRL2
after maturation (19, 20). Thus, the three receptors might play
key roles in the differential migration pattern of these antigen-
presenting cells. According to the conserved expression of
FPRL2 in monocytes and immature and mature DCs, its cog-
nate ligand could be generated all along the trafficking route of
these cells from the sites of inflammation and antigen uptake to
the secondary lymphoid organs. Thus, we searched for poten-
tial agonist(s) in various sources by reverse pharmacology. We
identified in the spleen a biological activity specific for FPRL2-
expressing cells and characterized it as the first natural ligand
displaying both a high affinity and a high specificity for
FPRL2. This new acetylated peptide, called F2L (FPRL2
ligand), is a potent chemoattractant for DCs and monocytes.
 
RESULTS
Isolation and identification of the F2L peptide 
as an endogenous ligand of FPRL2
 
As a screening assay, we developed CHO-K1 cell lines co-
expressing human FPRL2, apoaequorin, and G
 
 
 
16
 
. This al-
Figure 1. Purification from porcine spleen of the natural ligand of 
FPRL2. A porcine spleen homogenate was first fractionated by HPLC onto 
a Poros column (Step 1). The absorbance (AU) and biological activity on 
FPRL2-expressing CHO-K1 cells are shown. The luminescence measured in 
an aequorin-based assay (black bars) was normalized to the response ob-
tained for 20  M ATP. A1 (activity 1) and A2 (activity 2) represent the two 
active regions on the HPLC profile. They were processed together onto a 
C18 column (Step 2). Thereafter, A1 and A2 were purified separately onto 
an SEC (Step 3), a C4 column (Step 4), and for A1, a last C18 column (Step 
5). The x axis is magnified to focus on the region of interest. 
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lowed us to test fractions from human lymphoid organ
extracts, conditioned media of leukocyte populations, and
inflammatory fluids. A biological activity, specific for
FPRL2-expressing cell lines, was detected in fractions re-
sulting from the reverse phase HPLC fractionation of ex-
tracts from human spleen (not depicted). For practical rea-
sons, we tested fractions from porcine spleen prepared in a
similar way and identified two regions of the profile con-
taining specific activities for FPRL2 (activities A1 and A2;
Fig. 1). Starting from 350 g of porcine spleen, these two ac-
tivities were purified to homogeneity by five (A1) or four
(A2) successive HPLC steps, the first two being common
(Fig. 1). The sensitivity of both activities to proteinase K
suggested a peptidic nature (not depicted). The molecular
mass of the active compounds was estimated by size-exclu-
sion chromatography to 
 
 
 
6 kD for activity A1 and 3 kD for
activity A2. From the absorbance of the peaks and the
biological activities associated with them, the compound
present in peak A1 appeared more abundant but less active
than that of peak A2. The two fractions were analyzed by
SDS-PAGE and silver staining to quantify approximately the
active peptides by comparison with known amounts of
aprotinin and lysozyme (Fig. 2, D and F). A concentration
action curve performed on the same fractions in the
aequorin-based functional assay allowed us to estimate an
EC
 
50 
 
of 2.32 
 
  
 
1.84 nM (
 
n 
 
  
 
2) for A2 and 200 
 
  
 
54 nM
(
 
n 
 
  
 
4) for A1 (Fig. 2, G and E, respectively). Both peptides
were analyzed by mass spectrometry, either without (A2) or
after tryptic digestion (A1 and A2; Fig. 2, A and B). For A2,
analysis of the undigested peptide allowed us to identify the
entire microsequence as matching the first 21 amino acids of
a human intracellular heme-binding protein (HBP; sequence
data are available from GenBank/EMBL/DDBJ under ac-
cession no. NM 015987) with an amino-terminal acetyla-
tion (mol wt: 2,478.28 daltons; Fig. 2, A and B). For A1, six
peptides, of which four were fragments of the two longest
tryptic fragments shown in Fig. 2 B, were also consistent
with HBP. The porcine HBP was cloned by PCR from
liver cDNA using degenerate primers, which allowed us to
confirm the identification, and the perfect conservation of
the first 21 amino acids as compared with the human se-
quence. This sequence was later confirmed after the incor-
poration of porcine HBP expressed sequence tags in public
databases (data available from GenBank/EMBL/DDBJ un-
der accession no. AY662687). The two tryptic peptides
from A1 covered 50 amino acids in the amino-terminal do-
main of the 190–amino acid-long sequence of porcine HBP
(Fig. 2 C). We assume that the amino-terminal end of A1 is
common to that of A2, although it could not be demon-
strated. The carboxy-terminal end of A1 was not deter-
 
Figure 2. Identification of F2L as a high affinity natural ligand of 
FPRL2. 
 
(A) Mass spectrometry analysis of the undigested fraction A2 re-
sulting from step 4 using a Maldi Q-TOF mass spectrometer. (B) Sequences 
corresponding to the major peaks of the mass spectra of trypsin-digested 
A1 (step 5) and A2 (step 4) fractions or undigested A2. All microsequenced 
peptides were found to derive from the porcine HBP. The F2L peptide (A2 
fraction) is amino terminally acetylated. Ac, acetyl. (C) Amino acid sequence 
alignment of human, mouse, and porcine HBP. The sequence corresponding 
to the F2L peptide (represented in bold) is identical in human and porcine 
HBP. The region containing tryptic peptides recovered from fraction A1 is 
boxed (human HBP, NM 015987; murine HBP, NM 013546). (D) The A1 
fraction (step 5) was migrated onto SDS-PAGE together with 10, 50, and 
100 ng aprotinin as standards. The gel was silver stained, and it was esti-
mated that the major band (6 kD) contained around 300 ng of peptide. 
(E) Biological activity of the A1 fraction on CHO-K1 cells expressing human 
FPRL2 using the aequorin-based assay. (F) The A2 fraction (step 4) was mi-
grated onto SDS-PAGE together with 10 and 50 ng aprotinin as standards. 
The gel was silver stained and the amount of F2L (3 kD) was estimated to 
40 ng. (G) Biological activity of F2L (A2, step 4) on CHO-K1 cells expressing 
human FPRL2 using the aequorin-based assay. 
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The comparative pharmacology of the three FPRs was
then studied in more detail, using F2L and four reference
agonists of FPR and FPRL1 (FMLP, the hexapeptides
WKYMVM and WKYMVm, and the CCL23-derived
SHAAG peptide). Concentration action curves and the re-
sulting functional parameters were established both in the
aequorin-based assay and the cAMP accumulation assay after
stimulation by 10 
 
 
 
M forskolin (Fig. 3, A and B, and Table
I). Among the tested peptides, F2L was by far the most po-
tent on FPRL2, with an EC
 
50 
 
of 10 nM in the aequorin assay
and 5 nM in the cAMP assay. F2L also appeared as highly
specific, as a weak activity was obtained on FPRL1 (EC
 
50 
 
of
567 and 234 nM in the aequorin and cAMP assays, respec-
tively), whereas on FPR, only partial inhibition of cAMP ac-
cumulation was obtained for 1 
 
 
 
M F2L, and no activity was
detected in the aequorin assay up to 5 
 
 
 
M. For the other
peptides, the EC
 
50 
 
values obtained for FPR and FPRL1 (Ta-
ble I) were essentially as described in the literature (3, 4, 13).
However, significant differences with published data were
observed when testing the two W hexapeptides on the
FPRL2-expressing cells. Indeed, micromolar concentrations
of these peptides were required to activate FPRL2 (while ac-
tive at low nanomolar concentrations on FPR and FPRL1).
As described, FMLP and SHAAG were inactive on FPRL2.
To further confirm that F2L is a specific high affinity
ligand for FPRL2, we performed binding experiments. A
modified F2L peptide bearing a carboxy-terminal tyrosine
was found to display a potency similar to that of wild-type
F2L in the aequorin assay (not depicted). This peptide was
iodinated with 
 
125
 
I and used as a tracer. Saturation binding
assays, performed on FPRL2-expressing CHO-K1 cells, al-
lowed us to determine a K
 
D 
 
of 11.7 
 
  
 
4.9 nM (
 
n 
 
  
 
3) and a
mined precisely either, due to the large number of tryptic
sites after Arg
 
56 
 
of HBP. The purification was performed
three times with distinct protocols, and the same peptides
were identified by mass spectrometry in each case.
 
Comparative pharmacology and intracellular signaling of FPRs
 
The pharmacology and signaling pathways activated by the
three members of the human FMLP receptor family were in-
vestigated in CHO-K1 cells expressing the receptors with or
without G
 
 
 
16 
 
and apoaequorin (Fig. 3). The acetylated 21–
amino acid peptide, named F2L (for FPRL2 ligand), was syn-
thesized and tested in the aequorin-based assay on these three
cell lines as well as on wild-type CHO-K1 cells and CHO-K1
cells expressing chemerinR and other GPCRs. The synthetic
F2L peptide was shown to activate the FPRL2-expressing
cells with a potency similar to that of the native peptide puri-
fied from the spleen and, with a much lower efficiency,
FPRL1 and FPR (see below), but it was completely inactive
on all other cell lines tested (not depicted). F2L was also tested
in a cAMP accumulation assay on CHO-K1 cells expressing
FPRL2 but not G
 
 
 
16
 
. The synthetic peptide was found to in-
hibit the cAMP accumulation promoted by forskolin and was
unable to stimulate cAMP production by itself. In the same
cells, F2L also promoted intracellular calcium release at low
nanomolar concentrations (not depicted) and induced at pico-
molar concentrations the phosphorylation of the extracellular
signal–regulated kinase (ERK)1/2 mitogen-activated protein
(MAP) kinases (Fig. 3 I). Kinetics study of MAP kinase activa-
tion showed a maximal phosphorylation at 15 min (Fig. 3 J).
Calcium signaling was totally inhibited by pertussis toxin pre-
treatment, demonstrating the coupling of the FPRL2 receptor
to the G
 
i 
 
family of heterotrimeric G proteins (Fig. 3 G).
 
Table I.
 
Pharmacology of FPRs
 
Receptor Ligand
pEC
 
50
 
(aequorin assay)
pEC
 
50
 
(cAMP assay)
pIC
 
50
 
(binding assay)
FPRL2
 
F2L 8.02 
 
  
 
0.13 (
 
n
 
 
 
  
 
9) 8.24 
 
  
 
0.06 (
 
n 
 
  
 
4) 7.48 
 
  
 
0.003 (
 
n
 
 
 
  
 
3)
WKYMVm
 
 
 
6N T
 
 
 
6
WKYMVM
 
 
 
6
 
 
 
6N T
SHAAG
 
 
 
6
 
 
 
6
 
 
 
6
FMLP
 
 
 
6
 
 
 
6
 
 
 
6
 
FPRL1
 
F2L 6.26 
 
  
 
0.12 (
 
n
 
 
 
  
 
3) 6.65 
 
  
 
0.16 (
 
n
 
 
 
  
 
8)
 
 
 
6
WKYMVm 10.57 
 
  
 
0.10 (
 
n
 
 
 
  
 
3) NT 7.66 
 
  
 
0.15 (
 
n
 
 
 
  
 
3)
WKYMVM 10.04 
 
  
 
0.18 (
 
n
 
 
 
  
 
3) 10.27 
 
  
 
0.27 (
 
n
 
 
 
  
 
4) NT
SHAAG 9.27 
 
  
 
0.06 (
 
n
 
 
 
  
 
3) 9.23 
 
  
 
0.17 (
 
n
 
 
 
  
 
6) NT
FMLP 5.94 
 
  
 
0.03 (
 
n
 
 
 
  
 
3)
 
 
 
6N T
 
FPR
 
F2L
 
 
 
6
 
 
 
6
 
 
 
6
WKYMVm 9.18 
 
  
 
0.16 (
 
n
 
 
 
  
 
3) NT 7.03 
 
  
 
0.16 (
 
n
 
 
 
  
 
3)
WKYMVM 7.48 
 
  
 
0.08 (
 
n   3) 8.23   0.13 (n   4) NT
SHAAG  6  6N T
FMLP 9.39   0.33 (n   3) 10.15   0.08 (n   4) NT
Binding and activation of CHO-K1 cells expressing FPRL2, FPRL1, or FPR by F2L, FMLP, WKYMVm, WKYMVM, and SHAAG were studied using a binding assay, an aequorin-based 
assay, and an assay measuring the inhibition of cAMP accumulation. The EC50 and IC50 parameters of the dose-response curves were determined by nonlinear regression using 
Graphpad Prism software. The results represent the mean pEC50 or pIC50 (-log values of EC50 or IC50 )   SEM for at least three independent experiments (n).
NT, not tested.JEM VOL. 201, January 3, 2005 87
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Bmax of roughly 30,000 receptors per cell (Fig. 3 C). Compe-
tition binding assays were performed with F2L, which dis-
played an IC50 of 33.4   0.2 nM (Fig. 3 D and Table I). The
hexapeptides WKYMVM and WKYMVm, SHAAG, and
FMLP did not compete for FPRL2 binding up to concen-
trations of 3  M (not depicted). Next, we confirmed the
specificity of F2L for FPRL2 through binding experiments
on FPR and FPRL1-expressing CHO-K1 cells using [125I]-
WKYMVm as a tracer. The IC50 values for WKYMVm
were 22.5   7.6 nM on FPRL1 (Fig. 3 E) and 98.4   37.4
nM on FPR (Fig. 3 F), but no competition was observed for
F2L up to concentrations of 3  M.
By analogy with formyl peptides, we investigated the
role of the amino-terminal acetylation of F2L. The non-
acetylated peptide was synthesized and shown to display an
EC50 for FPRL2 similar to that of acetylated F2L (21.1   7.6
nM, n   3; Fig. 3 H). We also tested a truncated F2L variant
lacking the first six amino acids (F2L[7–21]) because mouse
intracellular HBP was originally described by Edman se-
quencing as lacking this amino-terminal part (21). This trun-
cated peptide was found to be totally inactive in aequorin
(Fig. 3 H) and binding assay (not depicted).
Distribution of human FPRL2
We investigated the presence of FPRL2 transcripts in vari-
ous leukocyte populations by RT-PCR (Fig. 4 A). As de-
scribed previously (19), FPRL2 transcripts were the most
abundant in monocytes and immature or mature monocyte-
derived DCs. Maturation of DCs was induced by either LPS,
LPS plus IFN- , or CD40L for 3–24 h, with no detectable
variation of the level of expression of FPRL2 transcripts (Fig.
4 A and not depicted). They were either absent or present at
very low levels in all other cell populations tested. Quantita-
tive RT-PCR was performed on a number of tissues using
DCs as reference. Transcripts were found at low levels in
most tissues and at higher levels in the lymph nodes, small
intestine, lung, and adipose tissue (Fig. 4 B).
Figure 3. Pharmacology of the FPRs. (A) Concentration action curves 
of F2L ( ), FMLP ( ), WKYMVm ( ), WKYMVM ( ), and SHAAG ( ) pep-
tides on CHO-K1 cells expressing FPR, FPRL1, or FPRL2 using the aequorin-
based assay. Results are expressed as percentage of the response elicited 
by 20  M ATP. (B) Concentration action curves of the same peptides on 
CHO-K1 cells expressing the three receptors using a cAMP accumulation 
assay. Results are expressed as percentage of the cAMP level obtained in 
the presence of 10  M forskolin but in the absence of agonists. FSK, forskolin. 
(C) Saturation binding assay (specific binding) on FPRL2-expressing CHO-K1 
cells using F2L bearing a carboxy-terminal [125I]Tyr as tracer. (D) Competi-
tion binding assay on FPRL2-expressing CHO-K1 cells using F2L-[125I]Tyr as 
tracer and F2L as competitor. (E and F) Competition binding assay on (E) 
FPRL1- and (F) FPR-expressing CHO-K1 cells using [125I]-WKYMVm as 
tracer and WKYMVm ( ) or F2L ( ) as competitors. (G) Stimulation by F2L 
of FPRL2-expressing CHO-K1 cells cultured in the absence or presence of 
100 ng/ml pertussis toxin using the aequorin-based assay. (H) Concentra-
tion action curves of acetylated ( ), nonacetylated ( ), and [7–21]F2L ( ) 
peptides on FPRL2-expressing CHO-K1 cells using the aequorin assay. (I) 
Immunodetection of phosphorylated ERK1/2 in FPRL2-expressing CHO-K1 
cells after stimulation by F2L for 10 min. (J) Kinetics of ERK1/2 activation 
after stimulation by 100 nM F2L. Each experiment displayed in A–I was 
repeated at least three times.A NOVEL ENDOGENOUS-SPECIFIC LIGAND FOR FPRL2 | Migeotte et al. 88
Monoclonal antibodies were generated against human
FPRL2 by genetic immunization and characterized by FACS
on CHO-K1 cell lines expressing FPR, FPRL1, or FPRL2
(Fig. 4 C). One of the three monoclonals (1C4) was essen-
tially specific for FPRL2, exhibiting poor recognition of
FPRL1. The two other antibodies (1D2 and 1E1) recognized
equally well both receptors. None, however, cross-reacted
significantly with FPR. We investigated the ability of the an-
tibodies to block F2L signaling on FPRL2-expressing CHO-
K1 cells. However, their blocking properties appeared weak,
as only partial inhibition of the signal was obtained with high
concentrations (50  g/ml) of 1C4 antibody (not depicted).
These antibodies were used to confirm the presence of the
receptor at the surface of DCs. The three monoclonals al-
lowed us to detect FPRL2 on immature and mature mono-
cyte-derived DCs, although at variable levels. FPRL2 ex-
pression could be detected in 16 out of 24 donors. The
experiments on one representative donor are displayed in Fig.
4 D. We then compared intracytoplasmic and surface expres-
sion of FPRL2 on DCs by performing FACS analysis after
permeabilization of the cells. We found significant intracellu-
lar expression of FPRL2 even for donors for which surface
expression was very weak or undetectable (Fig. 4 E). Addi-
tionally, down-regulation of cell surface FPRL2 was ob-
served when DCs were cultured in presence of 1  M F2L for
48 h (not depicted). Together, these data suggest that the
variation of expression among donors can be attributed to
trafficking parameters such as internalization of the receptor
after its stimulation by a ligand present in plasma. For four
tested donors, maturation of DCs by LPS induced a slight de-
crease in surface expression of FPRL2 (Fig. 4 F). Finally, we
evaluated the only variant of FPRL2 described to date (data
available from GenBank/EMBL/DDBJ under accession no.
AAA58482), which was characterized by an aspartic acid to
histidine substitution at position 338. No difference in ex-
pression or functional response (cAMP inhibition) was de-
tected after transient expression in HEK cells as compared
with the FPRL2 form used initially (not depicted).
Biological activity of F2L in primary immune cells
The biological function of F2L was investigated on leuko-
cyte populations. Given the role of FPR and FPRL1 in
chemoattraction, and the distribution of FPRL2, we focused
on the measurement of calcium mobilization and chemotaxis
on monocytes and monocyte-derived DCs. F2L promoted
intracellular Ca2  flux in immature DCs (Fig. 5 A) as well as
mature DCs (not depicted) in a dose-dependent manner.
The amplitude of the response, although variable according
to individuals, was comparable to that resulting from the
stimulation by 10 nM FMLP (Fig. 5 B). The response was
transient. According to the F2L concentration and the donor
(not depicted), it went back to baseline after 1–3 min. Out of
12 donors tested, a strong response was obtained in 7 cases, a
weak response in 2 cases, and no response for 3 donors. This
is attributed to the variable expression level of FPRL2 as de-
termined by FACS analysis. Calcium mobilization was also
Figure 4. Expression profile of human FPRL2. (A) Transcripts encod-
ing human FPRL2 were amplified by RT-PCR in a set of human leukocyte 
populations. act., activated; Mononucl., mononuclear cells; iDC, immature 
DCs; mDC, mature DCs. (B) Distribution of FPRL2 in a set of human tissues 
by using quantitative RT-PCR (Taqman). The data were normalized for the 
expression of GAPDH used as control. (C) Anti-FPRL2 monoclonal antibodies 
were characterized by FACS on CHO-K1 cells expressing FPR, FPRL1, and 
FPRL2. Bold solid line, 1C4; dotted line, 1D2; dashed line, 1E1; thin solid 
line, control labeling (IgG2a). The profiles of 1D2 and 1E1 are superim-
posed and cannot therefore be distinguished. (D) The expression of FPRL2 
was analyzed by FACS on immature DCs using the three monoclonal anti-
bodies. Bold solid line, anti-FPRL2 antibodies; thin solid line, control label-
ing (IgG2a). (E) Expression of FPRL2 on intact and permeabilized DCs using 
1C4. Bold solid line, 1C4; thin solid line, control labeling (IgG2a). (F) Expression 
of FPRL2 on immature (bold solid line) and mature (thin solid line) DCs using 
1D2. Dotted lines, control labeling (IgG2a).JEM VOL. 201, January 3, 2005 89
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The FPR family has been known for more than 10 yr.
Two of its members, FPR and FPRL1, were found to re-
spond to a number of endogenous or exogenous ligands and
have been involved in numerous physiological and patholog-
ical processes, including antimicrobial defense, mounting of
inflammatory responses, and development of amyloidogenic
diseases. The third receptor of this family, FPRL2, had so far
no high affinity natural agonist and was therefore still an or-
phan receptor. It displays an interesting expression profile, as
it is selectively expressed in DCs and monocytes.
In this study, we have identified a natural ligand for
FPRL2 by reverse pharmacology, using a bioassay based on
the expression of the receptor in a recombinant cell line.
Starting from the spleen, we have isolated and characterized
a new peptide, F2L, as the first natural agonist displaying
both high affinity and high selectivity for FPRL2. F2L is an
acetylated 21–amino acid peptide derived from the amino-
terminus of the intracellular HBP. It is highly conserved
across mammalian species (Fig. 2 C). F2L binds and activates
FPRL2 in the low nanomolar range, whereas the previously
described ligands of the receptor (annexin I–derived Ac-1-
25, bacterial Hp 2–20, and synthetic W peptides) are essen-
tially FPRL1 agonists displaying weak activities on FPRL2.
It should be noted that the synthetic hexapeptides WKY-
MVM and WKYMVm were initially described as high affin-
ity agonists of FPRL2 on the basis of experiments conducted
on purified leukocyte populations or FPRL2-expressing
HL-60 cells (18, 19). Other data contradict these observa-
tions, describing activities of these peptides in the micromo-
lar range on FPRL2 expressed in RINm5F (18) or HEK 293
cells (15). In our hands, these two peptides effectively re-
quired micromolar concentrations to elicit calcium influx in
FPRL2-expressing CHO-K1 cells, whereas they were active
at low nanomolar concentrations on FPR and FPRL1 ex-
pressed in the same system. It is likely that the early observa-
tions described above can be attributed to the endogenous
expression of either FPR, FPRL1, or another unknown re-
ceptor in the systems used.
The amino-terminal methionine of F2L is acetylated, a
modification that is found also in the amino-terminal peptide
of annexin I, and is reminiscent of the formylated methio-
nine of bacterial and mitochondrial peptides active on FPR.
We have shown that the acetyl moiety is not essential for the
activity of F2L in vitro, in contrast to the formyl group of
FMLP. However, the acetyl-methionine might play an im-
portant role in stabilizing the peptide in vivo, protecting it
from aminopeptidases and other proteases known to be acti-
vated in inflammatory situations.
Using blue sepharose chromatography, murine HBP was
initially purified from the liver in a search for new cytosolic
HBPs (21). Human HBP was later described as a monomeric
tetrapyrolle-binding protein (29). HBP transcripts can be
found in all tissues, but are particularly abundant in the kid-
ney, liver, and spleen. In mouse erythroleukemia cells, HBP
synthesis is stimulated by erythroid differentiation, and
HBP antisense oligonucleotides partially block the increase
Figure 5. Biological activity of F2L on primary immune cells. (A and 
B) Recording of Ca2  flux in monocyte-derived DCs in response to various 
concentrations of F2L (A) and 10 nM FMLP (B). (C) Recording of Ca2  flux 
in monocytes in response to 100 nM and 1  M F2L. (D and E) Chemotaxis 
of monocyte-derived human immature DCs (D) and PBMCs (E) in response 
to F2L. The displayed responses are representative of four donors out of 
five tested.
observed in purified monocytes in response to 100 nM F2L,
although the amplitude of the signal was lower than with
DCs (Fig. 5 C). Human F2L promoted ex vivo migration of
immature DCs and monocytes (Fig. 5, D and E). Cell migra-
tion in response to F2L was mainly due to chemotaxis rather
than chemokinesis as assessed in checkerboard experiments
(not depicted). Maximal chemotactic responses were ob-
tained for concentrations of 300 pM to 1 nM. The bell-
shaped chemotactic response, with a maximum correspond-
ing to concentrations below the EC50 derived from other
functional assays, is typically observed for other chemotactic
factors such as chemokines.
DISCUSSION
In the past few years, the functional characterization of or-
phan GPCRs has led to the identification of original patho-
physiological pathways, promoting the use of these newly
deorphanized receptors as candidate targets for drug devel-
opment. The use of orphan receptors in various types of bio-
assays has indeed allowed the discovery of new biological
mediators acting through GPCRs such as nociceptin/orpha-
nin FQ, orexins, ghrelin, and chemerin, or to the identifica-
tion of known molecules such as short fatty acids, succinate
and  -ketoglutarate, and prostaglandins as the natural ligands
of previously orphan GPCRs (22–28). Many of these recep-
tors have since raised considerable interest for their role in
human diseases and are now widely used in the drug discov-
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of heme content associated with this differentiation process
(21). The putative function of HBP is to buffer heme and
porphyrins synthesized in excess. As HBP is a cytosolic pro-
tein, its amino-terminal peptide fragments acting on FPRL2
could either be generated intracellularly by proteolytic pro-
cessing and then released, or alternatively, the whole protein
could be secreted and the cleavage could take place in the
extracellular compartment. The longer, less active HBP-
derived peptide isolated from the spleen could represent an
intermediate step in the generation of the final, fully active
agonist. HBP and/or its active fragments could be released
either through a nonconventional mode of secretion or sec-
ondary to cell death. We did not observe biological activity
on FPRL2-expressing cells in supernatants from CHO-K1
cells transfected with an expression vector containing the
full-size human HBP cDNA (not depicted). This suggests
that the processing leading to the active F2L peptide does not
occur in CHO-K1 cells and probably requires a specific en-
vironment. An increasing number of proteins devoid of sig-
nal peptide were shown to be released from the cells by un-
known mechanisms. IL-1  is generated from an intracellular
precursor by proteolytic cleavage by the caspase ICE, and the
unconventional mechanism by which it is released from the
cells is not known (30). Two intracellular peptides, Sun A
and B, were recently described as the ligands of the Dro-
sophila receptor Methuselah (31). Annexin I, a ligand of
FPR, FPRL1, and to a lower extent FPRL2, is also an intra-
cellular protein of 346 amino acids, which is externalized by
a still unclear mechanism when neutrophils adhere to the en-
dothelium. The acetylated amino-terminal domain of the
protein, which is exposed only in the presence of calcium
ions (32), is cleaved by proteolysis, and both the full-size
protein and the amino-terminal peptides bind the receptors
(33, 34). Another recently identified ligand of FPRL1, hu-
manin, is also an intracellular protein synthesized without
signal peptide and shown to be released from cells in a non-
conventional way. The humanin sequence was further shown
to induce the secretion of other proteins when fused to
them, thereby playing the role of an export signal (35).
F2L is a new member of the chemoattractant factor fam-
ily. By binding on FPRL2, it triggers the classical intracellu-
lar cascades stimulated by chemoattractants through the Gi
class of G proteins: stimulation of intracellular calcium re-
lease, inhibition of cAMP production, and activation of the
MAP kinases ERK1/2. The peptide is able to chemoattract
monocytes and immature DCs. It could therefore be in-
volved in the response of these cells to infection, inflamma-
tion, or cell death. DCs are known to process and present
antigens derived from infected, malignant, or allogeneic
cells. Recent evidence indicates that these cells are attracted
by dead or dying cells (36). The first self-molecules shown to
represent danger signals were the heat shock proteins gp96
or hsp70. They are released from necrotic cells and are able
to potently activate antigen-presenting cells (37). Intracellu-
lar nucleotides released under conditions of hypoxia, ische-
mia, inflammation, or mechanical stress, and crystalline uric
acid deriving from dead cells, were also shown to stimulate
DCs (38, 39). Apoptotic cells, in addition to engulfment sig-
nals, release chemotactic factors for phagocytes (40). Thus, it
is conceivable that F2L, released from HBP by proteolysis af-
ter cell suffering or cell death, contributes to the chemoat-
traction of monocytes and DCs through FPRL2. Therefore,
F2L and FPRL2 might be involved in the development of a
number of inflammatory diseases associated with cell death.
In this context, FPRL2 could represent an attractive target
for therapeutic approaches. However, the characterization of
the precise contribution of this system in specific human dis-
eases will require additional investigations.
MATERIALS AND METHODS
Expression of human FPRL2, FPRL1, and FPR. The human coding
sequences (data available from GenBank/EMBL/DDBJ accession nos
AC005946, M84562, and M60626, respectively) were amplified by PCR
from human genomic DNA, cloned into the pcDNA3 (Invitrogen) and
pEFIN3 (Euroscreen) vectors, and sequenced. The pEFIN3 constructs were
transfected using Fugene 6 into CHO-K1 cells expressing or not G 16 and
apoaequorin. G418-resistant clones were characterized for receptor expres-
sion by Northern blotting. A functional assay based on the luminescence of
mitochondrial aequorin was performed as described previously (41). Results
were expressed as relative light units or as the percentage of the response to
20  M ATP.
Purification of bioactive peptides. 350 g of frozen porcine spleen was
homogenized in four volumes of ice-cold 20% CH3CN in water. The homog-
enate was centrifuged at 10,000 g for 30 min at 4 C and snap-frozen in liquid
nitrogen. Aliquots of 200 ml of supernatant were diluted fourfold in 0.1%
TFA and loaded on a Poros R2 bead 4.6   150–mm column (Applied Bio-
systems) at 5 ml/min. A 5–70% CH3CN gradient (6%/min) in 0.1% TFA was
applied, and 1.25 ml fractions were collected and tested for functional activity
on FPRL2-expressing CHO-K1 cells in an aequorin assay. Two regions of
activity (A1 and A2) were detected on the HPLC profile. The corresponding
fractions were pooled, diluted fourfold in 0.1% TFA, and loaded at 1 ml/min
on a C18 4.6   250–mm column (Vydac), which was submitted to a 30–50%
CH3CN gradient in 0.1% TFA. Two regions of activity were detected and
subsequently treated separately. The 1-ml fractions corresponding to the first
(A1, lower CH3CN concentration) and the second (A2, higher CH3CN con-
centration) regions from two runs were vacuum concentrated to 50  l. A1
and A2 were diluted threefold in 30% CH3CN/0.05% TFA and 30%
CH3CN/0.1% TFA, respectively, and loaded on size-exclusion columns
(SECs; A1: TSK-gel Alpha-4000 [7.8   300 mm; Tosoh Biosep]; A2: Super-
dex peptide PE [7.5   300 mm; Amersham Biosciences) submitted to a 0.5
ml/min flow rate of dilution medium. The active 0.25-ml fractions from one
SEC were diluted fourfold in 0.1% TFA and loaded at 0.2 ml/min on a C4
2.1   250–mm column (Vydac), which was submitted to a 25–45% (A1) or
30–50% (A2) CH3CN gradient at 0.3%/min in 0.1% TFA. The fractions
were collected manually according to the absorbance profile. For A1, the ac-
tive fractions from one run were pooled, diluted fivefold in 0.1% TFA, and
loaded at 0.05 ml/min on a C18 1   250–mm column (Vydac), which was
submitted to a 23–50% CH3CN gradient at 0.45%/min in 0.1% TFA. The
fractions were collected manually. For A2, the purity of the final active frac-
tion was checked by loading an aliquot on a C18 1   250–mm column. The
purification was repeated three times with different protocols (i.e., the SEC
step was replaced by a reverse phase step on a C18 2.1   250–mm column
submitted to a CH3CN gradient in 0.1% H3PO4 as ion-pairing agent). The
protein concentration in active fractions was determined after SDS/PAGE by
comparison with aprotinin and lysozyme standards after silver staining.
Mass spectrometry analysis. The active fractions were vacuum dried,
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digested by 50 ng trypsin overnight or left intact, and purified by solid phase
extraction (C18 ZipTip; Millipore). The peptides were eluted in 1.5  l of
70% CH3CN/0.1% TFA onto a metallic MALDI target, dried, and then
mixed with 1.5  l of matrix mix (2 mg/ml 2,5-dihydroxybenzoic acid and
10 mg/ml  -cyano-4-hydroxycinnamic acid, 2 mM fucose, 5 mM ammo-
nium acetate). Mass spectrometry analysis was performed on a Q-TOF
Ultima Global mass spectrometer equipped with a MALDI source (Micro-
mass) and calibrated using the monoisotopic masses of tryptic and chymo-
tryptic peptides from bovine serum albumin. Ionization was achieved using
a nitrogen laser (337-nm beam, 10 Hz), and acquisitions were performed in
a V mode reflectron position. Microsequencing was performed by argon-
induced fragmentation after selection of the parent ion.
Synthetic peptides. Acetylated or nonacetylated MLGMIKNSLFGS-
VETWPWQVL (HBP[1–21], renamed F2L), NSLFGSVETWPWQVL
(F2L[7–21]), WKYMVM, and MLWRRKIGPQMTLSHAAG (SHAAG
peptide derived from CCL23 amino-terminus) were synthesized locally by
using the solid phase Fmoc strategy (42) or were custom made by Eurogen-
tec. WKYMVM and WKYMVm were purchased from Phoenix Pharma-
ceuticals and FMLP was purchased from Neosystem. Monoisotopic masses
and sequences of all peptides were verified by mass spectrometry. F2L and
WKYMVM from different origins displayed the same properties. At high
concentrations, HBP-derived peptides were dissolved in DMSO and heated
at 50 C for 10 min due to their high hydrophobicity. Intermediate dilutions
were made in 50% CH3CN and were further diluted 40-fold in assay buffer
to reach working concentration.
Quantitative RT-PCR. FPRL2 transcripts were detected by RT-PCR in
cDNA from human blood cell populations obtained commercially (CLON-
TECH Laboratories, Inc.) or prepared locally as described previously (43).
Primers for FPRL2 were 5 -CTGGCCACACCGTTCTGT-3  as forward
and 5 -GGCCATGGTAATGAACACGTT-3  as reverse. Amplification of
GAPDH transcripts was performed as a control of the quality of cDNA (not
depicted). FPRL2 transcripts were detected by quantitative RT-PCR (Taq-
Man) in total or polyA  RNA samples from human tissues obtained com-
mercially (CLONTECH Laboratories, Inc. and Ambion) or prepared locally
(DCs). Primers for FPRL2 were 5 -TTACCATGGCCAAGGTCTTTCT-
3  as forward, 5 -GCAGACTGTGATGATGGACATAGG-3  as reverse,
and 5 FAM-TCCTCCACTTCATTATTGGCTTCAGCGT-3 DABSYL
as probe, and for the reference housekeeping gene (GAPDH) were 5 -
GAAGGTGAAGGTCGGAGTC-3  as forward, 5 -GAAGATGGT-
GATGGGATTTC-3  as reverse, and 5 FAM-CAAGCTTCCCGTTCT-
CAGCC-3 DABSYL as probe. Primers were used at 900 nM and probes
were used at 200 nM. Standard curves were run systematically for the two
genes, and the transcript copy number of FPRL2 was normalized to the
GAPDH transcript copy number for each sample.
Monoclonal antibodies and flow cytometry. BALB/c mice were in-
jected with 100  g pcDNA3-FPRL2 as described previously (44). Sera
were tested by FACS on the CHO-K1-FPRL2 cell line, and immune mice
were used to generate monoclonal antibodies by standard hybridoma tech-
nology using the NSO myeloma cell line. The Ig class of selected hybrid-
omas was determined with a mouse monoclonal antibody isotyping kit
(IsoStrip; Boehringer). Flow cytometry was performed using anti-FPRL2
antibodies or control IgG2a at 1  g/ml (for CHO-K1 cells) or 5  g/ml (for
primary cells) in PBS containing 0.1% BSA, 0.1% sodium azide, and FITC-
conjugated   chain–specific goat anti–mouse IgG (Sigma-Aldrich) as sec-
ondary antibody. Fluorescence of 10,000 cells was assayed using a FACScan
flow cytofluorimeter (Becton Dickinson). Intracytoplasmic staining was
performed using the Cytoperm/Cytowash kit (Becton Dickinson) accord-
ing to the manufacturer’s instructions.
Intracellular cascade assays. The cAMP concentrations were deter-
mined using a homogeneous time-resolved fluorescence kit (Cis Bio Inter-
national). In brief, cells were detached, resuspended in Krebs-Ringer hepes
(KRH) buffer containing 1 mM 3-isobutyl-1-methylxanthine, and submit-
ted to 10  M forskolin alone or together with increasing concentrations of
agonists for 30 min at room temperature. The reaction was stopped by the
successive addition of cAMP-XL665 and anti-cAMP cryptate diluted in ly-
sis buffer. The plates were incubated for 60 min at room temperature and
read on a Rubystar fluorimeter (Labtech). Results were calculated from the
665:620 nm ratio and expressed in delta F (%). A calibration curve was ob-
tained by plotting delta F% versus cAMP concentrations. ERK1/2 activa-
tion was assayed by Western blotting using an anti–phospho-p42/44 mono-
clonal antibody (E10; Cell Signaling Technology) as described previously
(45). The aequorin-based assay was performed with or without overnight
pretreatment with 100 ng/ml pertussis toxin. It was shown that such pertus-
sis toxin pretreatment did not inhibit the functional response to ATP in
these cells. For the analysis of FPRL2 polymorphism, HEK cells were trans-
fected with a pcDNA3 vector containing the wild-type or Asp338His
FPRL2 cDNA by the calcium phosphate method. Cells were recovered
48 h later and used for FACS or cAMP accumulation experiments.
Binding assays. F2L with an additional carboxy-terminal tyrosine was
synthesized and found to display an EC50 similar to that of wild-type F2L in
the aequorin assay. 5  g of peptide was labeled with 2 mCi of 125I using the
Iodogen method (42). After separation of unbound 125I, the resulting
specific activity of the peptide was estimated to 900 Ci/mmole. [125I]-
WKYMVm (2,200 Ci/mmole) was purchased from PerkinElmer. FPRL2,
FPRL1, and FPR-expressing CHO-K1 cells were plated in 24-well plates
(200,000 cells per well for FPRL2 and 100,000 cells per well for the two
other receptors). The next day, the cells were washed twice with a KRH
buffer without NaCl containing 280 mM saccharose and, for FPRL1 and
FPR, 0.1% NaN3. For saturation binding assays, cells were incubated with
various amounts of F2L-[125I]Tyr and nonspecific binding was determined
by using 1  M F2L as competitor. For competition binding assays, cells
were incubated with 100,000 cpm of F2L-[125I]Tyr or 10,000 cpm of [125I]-
WKYMVm and various amounts of F2L or other peptides as competitors in
KRH buffer supplemented with 5% BSA for 90 min at room temperature.
Cells were washed twice with ice cold buffer, and total radioactivity was re-
covered with 1 M NaOH and counted in a gamma counter for 2 min.
Chemotaxis and Ca2  mobilization assays on primary cells. Mono-
cyte-derived DCs were generated either from the adherent fraction of PB-
MCs cultured with 800 U/ml GM-CSF and 500 U/ml Il-4, or from Per-
coll-purified monocytes cultured with 50 ng/ml GM-CSF and 20 ng/ml
IL-13 for 5–7 d. For Ca2  mobilization assay, monocytes were obtained by
negative selection with the Monocyte Isolation Kit II (Miltenyi Biotec).
Cell migration in response to F2L and FMLP and MIP-1  (CCL3) used as
controls was evaluated by using a 48-well microchemotaxis chamber tech-
nique as described previously (2). For Ca2  mobilization assays, monocyte-
derived DCs or monocytes (5   105 cells/ml in HBSS without phenol red
but containing 0.1% BSA and 1 mM Probenecid; Sigma-Aldrich) were
loaded with 4  M Fluo 4 (Molecular Probes) for 1 h at 20 C in the dark.
The loaded cells were washed twice, resuspended at 1–2   106 cells/ml, and
50  l of cell suspension was distributed per well in a 96-well plate (View-
plate; Packard Instrument Co.). Reading was performed in a Fluostar fluo-
rimeter (Labtech) at 25 C. 50  l of ligand-containing medium was injected,
and the fluorescence at 520 nm was recorded every second for 1–3 min.
Each condition was performed in triplicate, the mean fluorescence for each
time point was calculated, and the curves were normalized by subtracting
the mean value of the five measurements preceding the injection.
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